title: High-Affinity H7 Head and Stalk Domain-Specific Antibody Responses to an Inactivated Influenza H7N7 Vaccine After Priming With Live Attenuated Influenza Vaccine.
abstract: Recent studies have shown that live attenuated influenza vaccines (LAIVs) expressing avian influenza virus hemagglutinins (HAs) prime for strong protective antibody responses to an inactivated influenza vaccine (IIV) containing the HA. To better understand this priming effect, we compared H7 HA head and stalk domain-specific B-cell responses in H7N7 LAIV-primed subjects and non-H7-primed controls after a single dose of H7N7 IIV. As previously reported, H7N7 LAIV-primed subjects but not control subjects generated strong hemagglutination-inhibiting and neutralizing antibody responses to the H7N7 IIV. Here, we found that the quantity, epitope diversity, and affinity of H7 head-specific antibodies increased rapidly in only H7N7 LAIV-primed subjects after receipt of the IIV. However, all cohorts generated a vigorous, high-affinity, stalk-specific antibody response. Consistent increases in circulating memory B-cell frequencies after receipt of the IIV reflected the specificity of high-affinity antibody production. Our findings emphasize the value of LAIVs as a vehicle for prepandemic vaccination.
authors.affiliation: David H. Smith Center for Vaccine Biology and Immunology, Department of Microbiology and Immunology.
authors.forename: Jessica L
authors.initials: JL
authors.lastname: Halliley
authors.affiliation: Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring.
authors.forename: Surender
authors.initials: S
authors.lastname: Khurana
authors.affiliation: Department of Microbiology, Icahn School of Medicine at Mt. Sinai, New York, New York.
authors.forename: Florian
authors.initials: F
authors.lastname: Krammer
authors.affiliation: Division of Infectious Diseases, Department of Medicine.
authors.forename: Theresa
authors.initials: T
authors.lastname: Fitzgerald
authors.affiliation: Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring.
authors.forename: Elizabeth M
authors.initials: EM
authors.lastname: Coyle
authors.affiliation: Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring.
authors.forename: Ka Yan
authors.initials: KY
authors.lastname: Chung
authors.affiliation: Department of Microbiology and Immunology.
authors.forename: Steven F
authors.initials: SF
authors.lastname: Baker
authors.affiliation: Department of Biostatistics and Computational Biology, University of Rochester Medical Center.
authors.forename: Hongmei
authors.initials: H
authors.lastname: Yang
authors.affiliation: Department of Microbiology and Immunology.
authors.forename: Luis
authors.initials: L
authors.lastname: Martínez-Sobrido
authors.affiliation: Division of Infectious Diseases, Department of Medicine.
authors.forename: John J
authors.initials: JJ
authors.lastname: Treanor
authors.affiliation: Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland.
authors.forename: Kanta
authors.initials: K
authors.lastname: Subbarao
authors.affiliation: Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring.
authors.forename: Hana
authors.initials: H
authors.lastname: Golding
authors.affiliation: David H. Smith Center for Vaccine Biology and Immunology, Department of Microbiology and Immunology.
authors.forename: David J
authors.initials: DJ
authors.lastname: Topham
authors.affiliation: David H. Smith Center for Vaccine Biology and Immunology, Department of Microbiology and Immunology.
authors.forename: Mark Y
authors.initials: MY
authors.lastname: Sangster
mesh_terms: D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood*; D001402:B-Lymphocytes / Q000276:immunology; D015331:Cohort Studies; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D053126:Influenza A Virus, H7N7 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000276:immunology*; D007251:Influenza, Human / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D009500:Neutralization Tests; D014613:Vaccines, Attenuated / Q000276:immunology; D015164:Vaccines, Inactivated / Q000276:immunology
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D007252:Influenza Vaccines; D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated
keywords: Avian influenza; H7 hemagglutinin; anti-stalk antibodies; antibody affinity; live attenuated; memory B cells; vaccine
references.citation: Vaccine. 2010 Mar 2;28(10):2186-94
references.pmid: 20056191
references.citation: Vaccine. 2009 Aug 6;27(36):4953-60
references.pmid: 19540952
references.citation: Immunol Rev. 2011 Jan;239(1):167-77
references.pmid: 21198671
references.citation: J Infect Dis. 2011 Mar 1;203(5):666-73
references.pmid: 21282194
references.citation: Sci Transl Med. 2011 Jun 1;3(85):85ra48
references.pmid: 21632986
references.citation: J Infect Dis. 2012 Feb 15;205(4):610-20
references.pmid: 22207649
references.citation: Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2573-8
references.pmid: 22308500
references.citation: J Virol. 2012 May;86(10):5774-81
references.pmid: 22398287
references.citation: Proc Natl Acad Sci U S A. 2012 Jun 5;109(23):9047-52
references.pmid: 22615367
references.citation: PLoS One. 2012;7(8):e43603
references.pmid: 22928001
references.citation: PLoS Pathog. 2012 Sep;8(9):e1002920
references.pmid: 23028320
references.citation: PLoS One. 2012;7(12):e49704
references.pmid: 23239968
references.citation: J Immunol Methods. 2013 May 31;391(1-2):50-9
references.pmid: 23454005
references.citation: Clin Vaccine Immunol. 2013 Jun;20(6):867-76
references.pmid: 23576673
references.citation: J Infect Dis. 2013 Aug 1;208(3):413-7
references.pmid: 23633404
references.citation: J Infect Dis. 2013 Aug 1;208(3):418-22
references.pmid: 23633407
references.citation: Sci Transl Med. 2013 Aug 28;5(200):200ra114
references.pmid: 23986398
references.citation: Curr Opin Virol. 2013 Oct;3(5):521-30
references.pmid: 23978327
references.citation: PLoS One. 2014;9(2):e87962
references.pmid: 24533064
references.citation: Sci Transl Med. 2014 Apr 30;6(234):234ra55
references.pmid: 24786323
references.citation: J Infect Dis. 2014 Jun 15;209(12):1860-9
references.pmid: 24604819
references.citation: Clin Vaccine Immunol. 2014 Aug;21(8):1153-63
references.pmid: 24943383
references.citation: Proc Natl Acad Sci U S A. 2014 Sep 9;111(36):13133-8
references.pmid: 25157133
references.citation: J Virol. 2014 Nov;88(22):13260-8
references.pmid: 25210189
references.citation: Trends Microbiol. 2014 Nov;22(11):623-31
references.pmid: 25264312
references.citation: Vaccine. 2014 Nov 12;32(48):6421-32
references.pmid: 25284811
references.citation: Vaccine. 2014 Nov 28;32(50):6798-804
references.pmid: 25446831
references.citation: Nat Immunol. 2015 Mar;16(3):296-305
references.pmid: 25642821
references.citation: J Infect Dis. 2015 May 1;211(9):1408-17
references.pmid: 25378637
references.citation: J Infect Dis. 2015 Jul 1;212(1):86-94
references.pmid: 25492919
references.citation: Nat Rev Microbiol. 2005 Aug;3(8):591-600
references.pmid: 16064053
references.citation: N Engl J Med. 2006 Mar 30;354(13):1343-51
references.pmid: 16571878
references.citation: J Immunol. 2008 Feb 1;180(3):1758-68
references.pmid: 18209073
references.citation: Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3485-90
references.pmid: 18299574
references.citation: Vaccine. 2008 Mar 25;26(14):1742-50
references.pmid: 18336962
references.citation: PLoS Med. 2009 Apr 21;6(4):e1000049
references.pmid: 19381279
references.citation: Vaccine. 2009 Mar 18;27(13):1889-97
references.pmid: 19368768
references.citation: Nature. 2008 May 29;453(7195):667-71
references.pmid: 18449194
references.citation: Eur J Immunol. 2009 May;39(5):1260-70
references.pmid: 19404981
references.citation: Vaccine. 2009 Jun 8;27(28):3744-53
references.pmid: 19464558
references.citation: Sci Transl Med. 2010 Jan 20;2(15):15ra5
references.pmid: 20371470